Literature DB >> 25392858

Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.

Dario Cattaneo, Sara Baldelli, Simone Castoldi, Nitin Charbe, Valeria Cozzi, Serena Fucile, Emilio Clementi.   

Abstract

We document our experience with therapeutic drug monitoring (TDM) of antiretroviral agents (1807 determinations) carried out as day-by-day clinical practice for the optimization of drug dosing in HIV-infected patients. A significant proportion of patients had lopinavir, atazanavir and nevirapine trough concentrations exceeding the upper therapeutic threshold. Further studies are needed to identify good candidates/drugs for TDM, eventually allowing the selection of patients who may benefit from TDM-driven adjustments in antiretrovirals dosage.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25392858     DOI: 10.1097/qad.0000000000000440

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  2 in total

1.  Does lopinavir really inhibit SARS-CoV-2?

Authors:  Dario Cattaneo; Dario Cattaneo; Cristina Gervasoni; Mario Corbellino; Massimo Galli; Agostino Riva; Cristina Gervasoni; Emilio Clementi; Emilio Clementi
Journal:  Pharmacol Res       Date:  2020-05-11       Impact factor: 7.658

2.  Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?

Authors:  Sara Baldelli; Mario Corbellino; Emilio Clementi; Dario Cattaneo; Cristina Gervasoni
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.